High level expression of meningococcal class 1 protein was achieved in Escherichia coli using the p-GEMEX-1 vector, in which the protein was expressed in inclusion bodies (IB), as a fusion with the bacteriophage T7 gene 10 capsid protein. The fusion protein (FP) was engineered with a factor Xa protease site between the gene 10 and class 1 protein, but treatment with the enzyme resulted in cleavage at additional sites within the class 1 protein. Since it was not possible to remove the leader protein, the intact FP provided an alternative antigen for immunization. Antisera raised to FP, solubilized from IB and incorporated into liposomes, generated a subtype-specific response which was weakly bactericidal for meningococci. In order to remove ...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
A variety of adjuvants with the potential for use with experimental human vaccines were used for imm...
The porA gene from Neisseria meningitidis was cloned into the pRSETA vector and recombinant class 1 ...
The PorA protein of Neisseria meningitidis (subtype P1.7,16) was expressed as a recombinant protein ...
Infections with Neisseria meningitidis are characterized by life-threatening meningitis and septicem...
The class 1 protein (PorA) is a major component of the outer membrane of Neisseria meningitidis and ...
The entire gene encoding the class 1 outer membrane protein of Neisseria meningitidis is located on ...
Meningoccal meningitis remains a severe life-threatening infection. Present vaccines to combat the d...
Four serosubtypes (P1.7, 16, P1.7-2, 4, P1.19, 15 and P1.5-1, 10-4) of the PorA outer-membrane prote...
The opc gene from Neisseria meningitidis was cloned into the pRSETA vector, and recombinant protein ...
The SC protein is expressed by the strain of Neisseria meningitidis (44/76) used for production of t...
Immunization with recombinant class I outer-membrane protein from Neisseria meningitidis: influence ...
Biotechnologia Aplicada 1996; Vol. 13, No. 4. Expression In Escherichia coli And Immunological Chara...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
A variety of adjuvants with the potential for use with experimental human vaccines were used for imm...
The porA gene from Neisseria meningitidis was cloned into the pRSETA vector and recombinant class 1 ...
The PorA protein of Neisseria meningitidis (subtype P1.7,16) was expressed as a recombinant protein ...
Infections with Neisseria meningitidis are characterized by life-threatening meningitis and septicem...
The class 1 protein (PorA) is a major component of the outer membrane of Neisseria meningitidis and ...
The entire gene encoding the class 1 outer membrane protein of Neisseria meningitidis is located on ...
Meningoccal meningitis remains a severe life-threatening infection. Present vaccines to combat the d...
Four serosubtypes (P1.7, 16, P1.7-2, 4, P1.19, 15 and P1.5-1, 10-4) of the PorA outer-membrane prote...
The opc gene from Neisseria meningitidis was cloned into the pRSETA vector, and recombinant protein ...
The SC protein is expressed by the strain of Neisseria meningitidis (44/76) used for production of t...
Immunization with recombinant class I outer-membrane protein from Neisseria meningitidis: influence ...
Biotechnologia Aplicada 1996; Vol. 13, No. 4. Expression In Escherichia coli And Immunological Chara...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
Neisseria meningitidis lipopolysaccharide (LPS) has adjuvant properties that can be exploited to ass...
A variety of adjuvants with the potential for use with experimental human vaccines were used for imm...